WO2023170318 - COLLATERAL SENSITIVITY BASED DRUG CYCLING TO TREAT FUNGAL INFECTIONS
National phase entry is expected:
Publication Number
WO/2023/170318
Publication Date
14.09.2023
International Application No.
PCT/EP2023/056380
International Filing Date
13.03.2023
Title **
[English]
COLLATERAL SENSITIVITY BASED DRUG CYCLING TO TREAT FUNGAL INFECTIONS
[French]
PÉRIODICITÉ DE MÉDICAMENT BASÉE SUR UNE SENSIBILITÉ COLLATÉRALE AFIN DE TRAITER DES INFECTIONS FONGIQUES
Applicants **
KATHOLIEKE UNIVERSITEIT LEUVEN
KU Leuven Research & Development Waaistraat 6 - Box 5105
3000 Leuven, BE
Inventors
VAN DIJCK, Patrick
Lobbenstraat 119
3271 Scherpenheuvel-Zichem, BE
CAROLUS, Hans
Tieltsebaan 39
3272 Scherpenheuvel-Zichem, BE
Priority Data
22161580.0
11.03.2022
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1520 | |
| EPO | Filing, Examination | 8413 | |
| Japan | Filing | 587 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 5110 |
Total: 16204 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The invention relates to combinations of different antifungal compounds for use in the treatment or prevention of a fungal infection in an individual, wherein the antifungal compounds are administered in alternating and consecutive regimes of administration, wherein at least one antifungal is administered in a least to regimes of administration.[French]
L'invention concerne des combinaisons de différents composés antifongiques destinés à être utilisés dans le traitement ou la prévention d’une infection fongique chez une personne, les composés antifongiques étant administrés en régimes d’administration alternés et consécutifs, au moins un antifongique étant administré selon au moins deux régimes d’administration.